Thus, we measured the frequency of cells with active caspase-3 to identify the number of apoptotic cells following treatment with anti-Fas or recombinant TRAIL protein to test if enhanced expression of death receptors by irradiation and bortezomib treatment would in fact increase sensitivity to killing through FasL or TRAIL receptors in tumor cells. This evidence concerns the gene CASP3 and neoplasm.